<DOC>
	<DOCNO>NCT02052999</DOCNO>
	<brief_summary>The objective study determine efficacy safety PAC-14028 1 % cream Amorepacific Corporation patient erythema-telangiectatic papulopustular rosacea</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety PAC-14028 Cream Rosacea Patients</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male female patient age 20 65 year old Clinical diagnosis erythematotelangiectatic papulopustular rosacea accord National Rosacea Committee Expert Society Erythema severity ≥ 1 Telangiectasia severity ≥ 1 At least 3 papule pustules facial region IGA score ≥ 2 Voluntarily sign write informed consent form study participation Patients unable diagnose evaluated rosacea due tattoo scar facial area Patients unable diagnose evaluated rosacea due excess hair ( e.g. , mustache , beard , whisker etc . ) facial area Patients sensitive drug vehicle Previous administration oral retinoid vitamin A ( ≥10,000 units/day ) within 6 month prior visit 1 Previous use estrogen oral contraceptive within 3 month prior visit 1 Previous use topical retinoids oral antibiotic ( e.g. , tetracycline , tetracycline derivative , erythromycin , erythromycin derivative , sulfamethoxazole , trimethoprim ) oral steroid treatment facial rosacea within 1 month prior visit 1 Previous use topical steroid topical antibiotic , topical treatment rosacea ( e.g. , metronidazole , azelaic acid ) within 2 week prior visit 1 Presently undergoing anticoagulant therapy History hematologic disease Ocularonly , Phymatous rosacea , papulopustular rosacea patient require systemic antibiotic History laser treatment rosacea within 6 week prior visit 1 Alcoholic drug abuse patient Patients treat prohibited concomitant drug consider inevitably require treatment prohibit concomitant drug study period Renal function impairment creatinine level high twice maximum normal range Hepatic function impairment AST/ALT high twice maximum normal range Pregnant lactate woman , woman childbirth potential ( negative pregnancy test baseline visit study ) Participation another clinical study within 1 month prior screen Patients consider ineligible study participation principal investigator subinvestigator reason ; rosacea due medical ( liver disease , renal failure , etc . ) , psychotic , neuropathic cause rather skin disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>